Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer

High-grade serous ovarian cancer (HGSC) is an aggressive cancer with a worse clinical outcome. Therefore, studies about the prognosis of HGSC may provide therapeutic avenues to improve patient outcomes. Since genome alteration are manifested at the protein level, we integrated protein and mRNA data of ovarian cancer from The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) and utilized the sparse overlapping group lasso (SOGL) method, a new mechanism-driven variable selection method, to select dysregulated pathways and crucial proteins related to the survival of HGSC. We found that biosynthesis of amino acids was the main biological pathway with the best predictive performance (AUC = 0.900). A panel of three proteins, namely EIF2B1, PRPS1L1 and MAPK13 were selected as potential predictive proteins and the risk score consisting of these three proteins has predictive performance for overall survival (OS) and progression free survival (PFS), with AUC of 0.976 and 0.932, respectively. Our study provides additional information for further mechanism and therapeutic avenues to improve patient outcomes in clinical practice.

[1]  S. Lheureux,et al.  Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma , 2015, International journal of cancer.

[2]  N. Istfan,et al.  Fructose consumption and cancer: is there a connection? , 2012, Current opinion in endocrinology, diabetes, and obesity.

[3]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[4]  Meeta Pradhan,et al.  Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma , 2013, BMC Systems Biology.

[5]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[6]  C. Deng,et al.  Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. , 2014, Cancer research.

[7]  C. Cohen,et al.  Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis , 2003, Modern Pathology.

[8]  M. Yuan,et al.  Model selection and estimation in regression with grouped variables , 2006 .

[9]  Qing Zhao,et al.  Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA , 2015, Briefings Bioinform..

[10]  D. Cramer,et al.  A case-control study of galactose consumption and metabolism in relation to ovarian cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[12]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  Jian Huang,et al.  BMC Bioinformatics BioMed Central Methodology article Supervised group Lasso with applications to microarray data , 2007 .

[14]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[15]  Peter Bühlmann.  Regression shrinkage and selection via the Lasso: a retrospective (Robert Tibshirani): Comments on the presentation , 2011 .

[16]  Y. Ishikawa,et al.  ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. , 2008, Cancer research.

[17]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.

[18]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ER a Expression in Breast Cancer Cells , 2001 .

[19]  A. Fernie,et al.  Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[20]  Friedrich-Carl von Rundstedt,et al.  Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival , 2016, The Journal of urology.

[21]  Yiling Lu,et al.  Predicting time to ovarian carcinoma recurrence using protein markers. , 2013, The Journal of clinical investigation.

[22]  C. Ricciardelli,et al.  Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. , 2016, Translational research : the journal of laboratory and clinical medicine.

[23]  S. Lheureux,et al.  Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma. , 2014 .

[24]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[25]  L. Boros,et al.  Fructose induces transketolase flux to promote pancreatic cancer growth. , 2010, Cancer research.

[26]  R. Tibshirani,et al.  Regression shrinkage and selection via the lasso: a retrospective , 2011 .

[27]  M. Kanehisa.  A database for post-genome analysis. , 1997, Trends in genetics : TIG.

[28]  R. Tibshirani,et al.  (37) Medications as Independent Risk Factors of Delirium in Patients With COVID-19: A Retrospective Study , 2018, Journal of the Academy of Consultation-Liaison Psychiatry.

[29]  V. Ganapathy,et al.  Constitutive expression of the taurine transporter in a human colon carcinoma cell line. , 1992, The American journal of physiology.

[30]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[31]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[32]  G. Kenter,et al.  Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. , 2014, Gynecologic oncology.

[33]  C. Thompson,et al.  ATP citrate lyase is an important component of cell growth and transformation , 2005, Oncogene.

[34]  Xianglin Shi,et al.  Constructing Molecular Classifiers for the Accurate Prognosis of Lung Adenocarcinoma , 2006, Clinical Cancer Research.

[35]  A. Halama.  Metabolomics in cell culture--a strategy to study crucial metabolic pathways in cancer development and the response to treatment. , 2014, Archives of biochemistry and biophysics.

[36]  Daniel E Bauer,et al.  ATP citrate lyase inhibition can suppress tumor cell growth. , 2005, Cancer cell.

[37]  Satoru Miyano,et al.  Sparse Overlapping Group Lasso for Integrative Multi-Omics Analysis , 2015, J. Comput. Biol..

[38]  W. Ichikawa.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway , 2006, Gastric Cancer.

[39]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[40]  F. Kern,et al.  Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .

[41]  B. No̸rgaard-Pedersen,et al.  Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma , 2003, Cancer.

[42]  Lichun Fan,et al.  MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway , 2016, Tumor Biology.

[43]  Jean-Philippe Vert,et al.  Group Lasso with Overlaps: the Latent Group Lasso approach , 2011, ArXiv.

[44]  P. Goodfellow,et al.  Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target , 2017, Oncogene.

[45]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[46]  Wen-li Lu,et al.  [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages]. , 2008, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[47]  Noah Simon,et al.  A Sparse-Group Lasso , 2013 .

[48]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[49]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[50]  Takashi Ishikawa,et al.  Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection , 2011, PloS one.

[51]  V. Adam,et al.  Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression , 2017, The Prostate.

[52]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[53]  P. Bork,et al.  Bioinformatics in the post-sequence era , 2003, Nature Genetics.

[54]  A. Oberg,et al.  Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer , 2014, Cancer & Metabolism.

[55]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[56]  F. Hanefeld,et al.  Identification of ten novel mutations in patients with eIF2B‐related disorders , 2005, Human mutation.

[57]  Jun Li,et al.  A prognostic 4‐gene expression signature for squamous cell lung carcinoma , 2017, Journal of cellular physiology.